Ayala Pharmaceuticals Inc (ADXS)

[bill_y]

8 to 10 million short shares, lack of much buyer interest precipitated by orchestrated selling managed by an engineered trading bot are three other reasons..but that aside, the disruptive nature to SOC and the cost/benefit ratio the treatment offers has made it a primary target of current soc investors for all types of cancer..and it is currently in no ones interest to protect the share price..with market weakness we should see a gradual float down to 2.50..s/p range..whats to stop it?